1 / 20

RENAAL

RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist Losartan. RENAAL. R eduction of E ndpoints in N IDDM with the A II A ntagonist L osartan.

mohawk
Télécharger la présentation

RENAAL

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist Losartan

  2. RENAAL Reduction of Endpoints in NIDDM with the AIIAntagonist Losartan An investigator initiated, multicenter, double-blind, randomized, placebo-controlled study to evaluate the renal protective effects of losartan in hypertensive patients with Type 2 diabetes and nephropathy 1513 Patients; 250 Centers; 28 Countries • Steering Committee Chair B. M. Brenner, MD • Data and Safety Monitoring Committee Chair C.E. Mogensen, MD • Clinical Endpoint Adjudication Committee Chair S. Haffner, MD • Coordinating Center: Merck Research Labs Study Director S. Shahinfar, MD Brenner BM et al New Engl J Med2001;345(12):861-869.

  3. RENAAL Primary Hypothesis Long-term treatment with losartan versus placebo (alone or in combination with conventional anti hypertensive therapy*) in Type 2 diabetic patients with hypertension and nephropathy will increase the time to first event and decrease the incidence of doubling of sCr, ESRD or death. * Excluding ACEIs and other AIIAs Brenner BM et al New Engl J Med2001;345(12):861-869.

  4. RENAAL Secondary Hypothesis • Losartan compared to placebo (alone or in combination with conventional antihypertensive therapy*) in hypertensive patients with Type 2 diabetes and nephropathy will: • increase the time to first event and decrease the incidence of cardiovascular morbidity/mortality • reduce proteinuria • decrease the rate of progression of renal disease * Excluding ACEIs and other AIIAs Brenner BM et al New Engl J Med2001;345(12):861-869.

  5. RENAAL Study Design Losartan 100 mg qd (+CT) Losartan 100 mg qd (+CT) Losartan 50 mg qd (+CT) Maintain conventional antihypertensive therapy (CT)* (excluding ACEI, AIIA) Goal trough BP: < 140/<90 mmHg n=1513 Placebo (+CT) Placebo (+CT) Placebo (+CT) 6 Wks 4 Wks 8 Wks Mean follow-up 3.4 years *CT=conventional therapy: Open-label calcium-channel blocker, diuretic, beta blocker, alpha blocker, or centrally acting agents. Brenner BM et al J Renin-Angio-Aldo System 2000;1(4):328-335.

  6. RENAAL Inclusion/Exclusion Criteria Inclusion criteria Type 2 diabetes Age 31-70 years Proteinuria:urine alb:cr >300 mg/g, >25 mg/mmol Serum Creatinine: 1.3-3.0 mg/dl, 115-265 µmol/L* Exclusion criteria Type 1 diabetes Known non-diabetic renal disease or renal artery stenosis Recent history of MI, CABG, PTCA, CVA, TIA History of heart failure HbA1c >12% *Lower limit 1.5 mg/dl (133 µmol/L) in male patients >60 kg Brenner BM et al J Renin-Angio-Aldo System 2000;1(4):328-335. Brenner BM et al New Engl J Med2001;345(12):861-869.

  7. RENAAL Enrollment by Regionn=1513 Asia 17% North America 46% Europe 19% Latin America 18% Brenner BM et al New Engl J Med2001;345(12):861-869.

  8. RENAAL Baseline Characteristics (I) Losartan (+CT) (n=751) 60 62 38 16 17 48 19 2 152 82 30 Placebo (+CT) (n=762) 60 65 35 18 14 50 18 1 153 82 29 Age, years Male, % Female, % Race, % Asian Black Caucasian Hispanic Other Systolic (mmHg) Diastolic (mmHg) BMI (kg/m2) % Brenner BM et al New Engl J Med2001;345(12):861-869.

  9. RENAAL Primary Composite Endpoint and Components Losartan (+CT) (n=751) n (%) 327 (43.5) 162 (21.6) 147 (19.6) 158 (21.0) 255 (34.0) Placebo (+CT) (n=762) n (%) Composite and Components % Risk Reduction 16 25 28 -2 20 DsCr, ESRD, Death Doubling of sCr ESRD Death ESRD or Death P-Value 0.02 0.006 0.002 0.88 0.01 95% CI (2, 28) (8, 39) (11, 42) (-27, 19) (5, 32) 359 (47.1) 198 (26.0) 194 (25.5) 155 (20.3) 300 (39.4) Brenner BM et al New Engl J Med 2001;345(12):861-869.

  10. 30 20 10 30 0 0 12 24 36 48 P 20 L 10 50 0 40 0 12 24 36 48 30 20 10 0 0 12 24 36 48 RENAAL Primary Components ESRD Risk Reduction: 28% P p=0.002 % with event L Doubling of Serum Creatinine Risk Reduction: 25% p=0.006 Months P (+ CT) 762 715 610 347 42 L (+ CT) 751 714 625 375 69 % with event ESRD or Death Risk Reduction: 20% p=0.01 P % with event L Months P (+ CT) 295 762 689 554 36 L (+ CT) 52 751 692 583 329 Months P (+ CT) 762 715 610 347 42 L (+ CT) 751 714 625 375 69 Brenner BM et al New Engl J Med2001;345(12):861-869. 0902CZR01NL537SS0901

  11. RENAALBlood Pressures (mmHg) Baseline Year 1 Year 2 Study End L (+CT) S/D 152/82 146/78 143/77 140/74 P (+CT) S/D 153/82 150/80 144/77 142/74 L (+CT) MAP 105.5 100.9 99.1 95.9 P (+CT) MAP 106.0 103.1 99.7 96.8 L (+CT) PP 69.4 67.8 66.2 66.7 P (+CT) PP 70.8 69.8 67.1 67.4 S/D: Systolic/Diastolic MAP: Mean arterial pressure PP: Pulse pressure L = losartan P = placebo CT = conventional therapy Brenner BM et al New Engl J Med 2001;345(12):861-869.

  12. RENAALDose of Losartan • The daily dose of losartan ranged from 50-100 mg Losartan* n=751 % 71 100 mg QD *Patients who took the dose more than 50% of the time. Brenner BM et al New Engl J Med 2001;345(12):861-869.

  13. RENAALConcurrent Antihypertensive Medications Losartann=751 77.9 60.7 83.8 40.2 34.1 18.0 Placebon=762 81.1 63.9 84.0 45.7 36.7 21.7 • Therapeutic Class • Calcium-Channel Blocker (%) • - Dihydropyridine (%) • Diuretic (%) • Alpha blocker (%) • Beta blocker (%) • Centrally acting agents (%) Brenner BM et al New Engl J Med 2001;345(12):861-869. .

  14. RENAALSecondary Composite Endpointand Components Losartan (+CT)(N=751) n (%) 247 (32.9) 89 (11.9) 50 (6.7) Placebo (+CT) (N=762) n (%) 268 (35.2) 127 (16.7) 68 (8.9) Composite and Components % RiskReduction 10 32 28 P-Value 0.26 0.005 0.08 CV Morbidity/Mortality Heart Failure MI Brenner BM et al New Engl J Med 2001;345(12):861-869.

  15. 20 15 10 5 0 RENAALFirst Hospitalization for Heart Failure Risk Reduction: 32% p=0.005 P % with event L 0 12 24 36 48 Months P (+CT) 762 685 616 375 53 L (+CT) 751 701 637 388 74 L = losartan P = placebo CT = conventional therapy Brenner BM et al New Engl J Med 2001;345(12):861-869.

  16. RENAALChange from Baseline in Proteinuria 40 20 P 0 Median Percent Change p<0.001 -20 35% Overall Reduction -40 L -60 0 12 24 36 48 Months P (+CT) 762 632 529 390 130 130 130 130 130 130 L (+CT) 751 661 558 438 167 167 167 167 167 167 Proteinuria measured as the urine albumin:creatinine ratio from a first morning void. L = losartan P = placebo CT = conventional therapy Brenner BM et al New Engl J Med 2001;345(12):861-869.

  17. RENAALRate of Progression of Renal Disease (median 1/sCr Slope) p=0.01 18% reduction -.08 -0.069 -0.056 -.06 dl/mg/yr -.04 -.02 0 Losartan Placebo sCr=serum creatinine (+CT) (+CT) Brenner BM et al New Engl J Med 2001;345(12):861-869.

  18. RENAAL Summary (I) • In hypertensive patients with Type 2 diabetes and nephropathy: • losartan delayed the onset of the primary composite endpoint (DsCr/ESRD/Death) and delayed the progression to ESRD. • losartan reduced proteinuria and the rate of decline in renal function (1/sCr slope). • losartan reduced the incidence of hospitalization for heart failure. • these benefits were largely independent of achieved blood pressure. Brenner BM et al New Engl J Med 2001;345(12):861-869.

  19. RENAAL Summary (II) • In hypertensive patients with Type 2 diabetes and nephropathy: • losartan and placebo, on a background of conventional therapy, showed no significant difference on all-cause mortality, MI, stroke, revascularization, hospitalizations for unstable angina, and death due to CV disease. • losartan was generally well tolerated in this patient population. Brenner BM et al New Engl J Med 2001;345(12):861-869.

  20. RENAALConclusions • Losartan confers significant benefits on renal outcomes in Type 2 diabetic patients with hypertension and nephropathy. • Losartan therapy results in a significant reduction in hospitalizations for heart failure. • Losartan is generally well tolerated. • Benefits of losartan seen in RENAAL complement many previous losartan studies which demonstrate a reduction in microalbuminuria and macroalbuminuria. Brenner BM et al New Engl J Med 2001;345(12):861-869.

More Related